Your new post is loading...
EU-Funded Consortium led by immatics and BioNTech to Advance a Novel Class of Fully Personalized Therapeutic Cancer Vaccines into Clinical Trials for Brain Cancer
Via Krishan Maggon
|
Scooped by Gilbert C FAURE from Cancer Immunotherapy Review and Collection |
Scoop.it!
Via Krishan Maggon
GAPVAC was launched in 2013 designed to create, manufacture and develop actively personalized vaccines (APVACs) tailored to the individual characteristics of the patient's tumor and immune system. It is based on combining latest state-of-the-art technologies, including next-generation sequencing (NGS), high-sensitivity mass spectrometry and innovative immunomonitoring approaches to generate an optimal therapy for the individual patient.
The consortium is supported by a €6 million grant from the European Union Framework 7 (EU FP7) program.